This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC3B0CQ_M.jpg
The Baupost Group’s holding in Akebia Therapeutics, Inc. were completely closed with the transaction.
The Baupost Group first bought Akebia Therapeutics, Inc. stock in the fourth quarter of 2018. The Baupost Group also owns Theravance Biopharma, Inc. (NASDAQ:TBPH). Akebia Therapeutics, Inc. was its pre-sell number two position by number of shares and market value among pharmaceuticals stocks.
Other investors who also sold all their Akebia Therapeutics, Inc. shares include Millennium Management. Contrary to the Baupost Group, California State Teachers Retirement System, the T. Rowe Price Equity Income Fund, and Victory Capital Management added to AKBA shares.
The Baupost Group also added to their share in Viasat, Inc. (VSAT) and Translate Bio, Inc. (NASDAQ:TBIO). The total value of the shares bought is estimated at around $103 million.
